Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

Folate increases risk of breast cancer in women with certain genetic make-up

In most women folate, a type of B vitamin, reduces the risk of breast cancer. However, in women with a certain genetic make-up it has shown to be the opposite: folate raises the risk of breast cancer.

7 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Innovative drug design wins medical research prize

The development of a new way to treat iron overload disease has won the 2010 Sir Zelman Cowen Universities Fund Prize for Medical Research.

1 Apr 2010

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today jointly announced that the companies have entered into a license, development and commercialization agreement related to Feraheme® (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

The European Hematology Association and the American Society of Hematology have selected Ingmar Bruns, MD, as the seventh recipient of the EHA-ASH Research Exchange Award, which serves to strengthen ties between North American and European scientific communities.

31 Mar 2010

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide™/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

4 kg liver tumor removed from 60 year old Nigerian

A team of doctors led by Dr Ramcharan Thiagarajan, Consultant Surgical Gastroenterology & Hepato Pancreatic Biliary Surgery, Fortis Hospitals, Bangalore (formerly Wockhardt Hospitals) recently performed a high risk surgery on a 60 year old Nigerian to remove a perilous tumor weighing 4 kilos surrounding his liver.

29 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

Identification of two new proteins in the Fanconi anemia DNA repair pathway may help explain genetic instability in people with Fanconi anemia and how otherwise healthy people are susceptible to cancer from environmentally triggered DNA damage.

26 Mar 2010

Pregnant breast cancer patients can receive chemotherapy without endangering baby health

Women who discover they have breast cancer while they are pregnant can be treated with chemotherapy without endangering the health of their unborn baby, according to research to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).

26 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Inexpensive lab tests can help protect people from chronic kidney disease

No matter what Washington does on health reform, there's a lot you can do to reform your own health -- and two of the best places to start are your kidneys.

20 Mar 2010

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

AMAG Pharmaceuticals, Inc. today announced that one abstract has been accepted for presentation at the National Kidney Foundation 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL.

19 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Anemia News and Research

Further Reading

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Folate increases risk of breast cancer in women with certain genetic make-up

StockPreacher.com releases investment report on Repros Therapeutics

Innovative drug design wins medical research prize

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

New medicines to fight diseases of particular concern to African Americans

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

4 kg liver tumor removed from 60 year old Nigerian

WinRho SDF for ITP: Cangene announces new safety information

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

Pregnant breast cancer patients can receive chemotherapy without endangering baby health

Evotec AG reports financial results and corporate updates for 2009

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

AARDA launches campaign on family AQ

Inexpensive lab tests can help protect people from chronic kidney disease

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News